Related references
Note: Only part of the references are listed.Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian et al.
THYROID (2022)
Radical or Not-So-Radical Prostatectomy: Do Surgical Margins Matter?
Ioanna Maria Grypari et al.
CANCERS (2022)
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer
Carlotta Giani et al.
THYROID (2021)
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Diana Bradford et al.
CLINICAL CANCER RESEARCH (2021)
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Christelle de la Fouchardiere et al.
EUROPEAN JOURNAL OF CANCER (2021)
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies
Mahesh Saqcena et al.
CANCER DISCOVERY (2021)
Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
Paula Soares et al.
ENDOCRINE PATHOLOGY (2021)
RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer
Desiree Deandreis et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring
Martina Zanchetta et al.
PLOS ONE (2021)
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
Matthew H. Taylor et al.
THYROID (2021)
Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
Makoto Tahara et al.
EUROPEAN JOURNAL OF CANCER (2021)
MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
S. Leboulleux et al.
ANNALS OF ONCOLOGY (2021)
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
Janice Kim et al.
CLINICAL CANCER RESEARCH (2021)
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hurthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).
Eric Jeffrey Sherman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2021)
Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer
Lionel Groussin et al.
THYROID (2021)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcSe Pembrolizumab Study from Unicancer.
Sophie Leboulleux et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer
Laura Valerio et al.
EUROPEAN THYROID JOURNAL (2021)
Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network
Francoise Bonichon et al.
ENDOCRINE (2021)
The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
Jiajun Liu et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data
M. D. Aydemirli et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences
Chie Masaki et al.
THYROID (2020)
Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
Bryan Haugen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Larotrectinib treatment of advanced TRK fusion thyroid cancer
M. E. Cabanillas et al.
ANNALS OF ONCOLOGY (2020)
A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer
Y-S. Lin et al.
ANNALS OF ONCOLOGY (2020)
Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
Y. Chi et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial
B. Haugen et al.
ANNALS OF ONCOLOGY (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer
Lionel Groussin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria
G. Rendl et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2020)
A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
M. S. Brose et al.
ANNALS OF ONCOLOGY (2020)
Locally unresectable differentiated thyroid cancer: outcomes and perspectives
L. Lamartina et al.
ENDOCRINE (2020)
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Lara A. Dunn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy
Mona M. Sabra et al.
CLINICAL ENDOCRINOLOGY (2019)
Redifferentiation of a BRAFK601E-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment
Sophie Leboulleux et al.
THYROID (2019)
Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association
R. Michael Tuttle et al.
THYROID (2019)
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy
L. D. Locati et al.
EUROPEAN JOURNAL OF CANCER (2019)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Filetti et al.
ANNALS OF ONCOLOGY (2019)
Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma
M. Barat et al.
EUROPEAN JOURNAL OF RADIOLOGY (2019)
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine- refractory differentiated thyroid cancer
Makoto Tahara et al.
EUROPEAN JOURNAL OF CANCER (2019)
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
Glenn J. Hanna et al.
CLINICAL CANCER RESEARCH (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice
Amandine Berdelou et al.
THYROID (2018)
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer
Francoise Borson-Chazot et al.
THYROID (2018)
The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer
Marie Terroir et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer
Desiree Deandreis et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
Jaume Capdevila et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial
Marcia S. Brose et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality
Rengyun Liu et al.
JAMA ONCOLOGY (2017)
Tumor Volume Doubling Time of Pulmonary Metastases Predicts Overall Survival and Can Guide the Initiation of Multikinase Inhibitor Therapy in Patients With Metastatic, Follicular Cell-Derived Thyroid Carcinoma
Mona M. Sabra et al.
CANCER (2017)
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
Manisha H. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review
Ana Albero et al.
ENDOCRINE-RELATED CANCER (2016)
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study
Christelle de la Fouchardiere et al.
TARGETED ONCOLOGY (2016)
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
Bruce Robinson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer
Livia Lamartina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Inigo Lancia et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Biologic and Clinical Perspectives on Thyroid Cancer
James A. Fagin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1 b KEYNOTE-028 study.
Janice M. Mehnert et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012
Aubrey A. Carhill et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Gerald S. Falchook et al.
THYROID (2015)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments
Laura D. Locati et al.
CANCER (2014)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Martin Schlumberger et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Vincenzo Marotta et al.
CLINICAL ENDOCRINOLOGY (2013)
Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases
M. M. Sabra et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Julio C. Ricarte-Filho et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine-Refractory Thyroid Carcinoma
Eric J. Sherman et al.
THYROID (2013)
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma
Marcia S. Brose et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer
Azeez Farooki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Sophie Leboulleux et al.
LANCET ONCOLOGY (2012)
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
D. Deandreis et al.
ENDOCRINE-RELATED CANCER (2011)
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
Debyani Chakravarty et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Role of FDG PET/CT and Chest CT in the Follow-up of Lung Lesions Treated with Radiofrequency Ablation
Desiree Deandreis et al.
RADIOLOGY (2011)
Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy
Akira Miyauchi et al.
THYROID (2011)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma
S. I. Sherman
CLINICAL ONCOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
David S. Cooper et al.
THYROID (2009)
Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma
Michael Rivera et al.
CANCER (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Motesanib diphosphate in progressive differentiated thyroid cancer
Steven I. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism
C. Durante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy
C. Durante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis - A clinicopathologic study of 58 patients
D Hiltzik et al.
CANCER (2006)
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
RJ Robbins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
